- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Leads Biolabs begins melanoma trial for bispecific antibody | 2 | Investing.com | ||
| Fr | Leads Biolabs: Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig | 80 | PR Newswire | NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first... ► Artikel lesen | |
| Fr | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN MELANOMA PHASE IB/II TRIAL OF OPAMTISTOMIG | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 08.09. | LEADS BIOLABS-B (09887): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | - | HKEx | ||
| 08.09. | LEADS BIOLABS-B (09887): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | - | HKEx | ||
| 29.08. | LEADS BIOLABS-B (09887): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 25.08. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-034 DOSED FIRST PATIENT IN PHASE II TRIAL | 1 | HKEx | ||
| 21.08. | LEADS BIOLABS-B (09887): STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | - | HKEx | ||
| 19.08. | LEADS BIOLABS-B (09887): DATE OF BOARD MEETING | 1 | HKEx | ||
| 14.08. | Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma | 75 | PR Newswire | NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful... ► Artikel lesen | |
| 11.08. | LEADS BIOLABS-B (09887): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 07.08. | LEADS BIOLABS-B (09887): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION | 1 | HKEx | ||
| 31.07. | Leads Biolabs' IPO points to biotech rebound in Hong Kong | 3 | KrASIA | ||
| 25.07. | Chinese antibody developer Leads Biolabs hits Hong Kong stock exchange in $189M IPO | 2 | FierceBiotech | ||
| 25.07. | LEADS BIOLABS-B (09887): CHANGE IN COMPOSITION OF NOMINATION COMMITTEE AND APPOINTMENT OF LEAD INED | 1 | HKEx | ||
| 25.07. | Leads Biolabs lists on HKEX, raises $189 million in IPO | 1 | Investing.com | ||
| 25.07. | Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering | 130 | PR Newswire | NANJING, China, July 24, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the... ► Artikel lesen | |
| 24.07. | LEADS BIOLABS-B (09887): ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | - | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
Das Unternehmen NANJING LEADS BIOLABS CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.